Magí Farré Albaladejo

Magi Farré is professor of Pharmacology at the School of Medicine of Universitat Autònoma de Barcelona and head of the Clinical Pharmacology Unit at Germans Trias i Pujol University Hospital in Badalona. He has developed his main research area in the field of human pharmacology of drugs of abuse and medications, being one of the few clinical researchers in this area. Farré has worked on the evaluation of pharmacokinetics and the acute and chronic effects of different drugs of abuse. He has extensive experience in pharmacogenetics with studies of the influence of genetic polymorphisms on the pharmacokinetics and effects of medications and drugs of abuse, highlighting the influence of polymorphisms of CYP2D6, CYP2C9, CYP3A4, CYP1A2, COMT, DAT, 5-HT1AR, ALDH5A1 or opioid or cannabinoid receptors. Most of the research projects in which he has been a PI/CI incorporate pharmacogenetic determinations. The most recent ones, which are currently underway, are on cannabis and synthetic cathinones.

For more than ten years, Farré has participated in numerous projects on human pharmacology of new psychoactive substances, highlighting his work on MDMA (midomafetamine), 2C-B, 2C-E, mephedrone, methylone and other synthetic cathinones, synthetic and natural cannabinoids (cannabis with high THC content), GHB, binge drinking, alcohol combined with energy drinks, cannabis and the combination of cannabis and alcohol. He has participated in clinical trials for the treatment of substance use disorders, especially alcohol and cocaine, in addition to the use of ayahuasca for severe grief therapy. More recently, he has been part of research teams on emerging infectious diseases, participating in clinical trials of treatments for COVID-19, including vaccines, as well as MPOX epidemiology.

For five years, he has been working mainly on the human pharmacology of different forms of administration of cannabis preparations (oral: tea and oil; inhaled: vaporizer, different preparation with variable contents of THC/CBD), synthetic cannabinoids (JWH-122, JWH-210, UR-144), synthetic cathinones ( mephedrone, methylone, MDPV, clephedrone [4-CMC], ethylhexedrone [Hexen] and ethylpentedrone [NEP], alpha-PVP, alpha-PHiP, clophedrone [3-CMC]), as well as the combination of alcohol and psychostimulants and consumption of alcohol in binge-drinking. All these clinical studies are conducted in humans and, when possible, include men and women.

Contact: mfarre.germanstrias(ELIMINAR)@gencat.cat
ORCID: 0000-0001-8338-7543